Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I-II trial of sunitinib and/or nivolumab plus chemotherapy in advanced soft tissue and bone sarcomas
2024-514776-40-00Phase 2Completed
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of sunitinib, nivolumab, epirubicin, ifosfamide, methotrexate and 2 more in soft tissue sarcoma (STS), bone cancer, Malignant Fibrous Histiocytoma (MFH) and 9 more (4 arms), sponsored by Spanish Group for Research on Sarcoma. Primary endpoints: Recommended phase II dose, 6-month progression-free survival rate and 3 more. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)bone cancerMalignant Fibrous Histiocytoma (MFH)leiomyosarcoma (LMS)osteosarcoma (OS)
Beyond the preview
Go deeper on 2024-514776-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514776-40-00.